Guggenheim Upgrades Sage Therapeutics (SAGE) to Buy
- Second half starts with a fresh drubbing for stocks
- Kohl's (KSS) Plunges 15% After Reportedly Terminating Sale Talks with Franchise Group
- Micron (MU) Shares Drop 4% on Significant Q4 Guidance Miss
- JPMorgan 'Not as Worried as the Street' on Apple (AAPL) Heading into Earnings
- Oil prices up 2% on supply outages
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Guggenheim analyst Yatin Suneja upgraded Sage Therapeutics (NASDAQ: SAGE) from Neutral to Buy with a price target of $55.00.
Shares of Sage Therapeutics closed at $42.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Atlantic Equities Upgrades First Republic Bank (FRC) to Overweight
- UPDATE: JPMorgan Downgrades Huntington Bancshares (HBAN) to Neutral
- Northland Upgrades AMD Stock to Outperform as Macro Headwinds are Now Priced In
Create E-mail Alert Related CategoriesUpgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!